FDA guidance on M7(R2) Assessment and control of DNA-Reactive (Mutagenic) Impurities in Pharmaceuticals

Assessment and control of DNA Mutagenic Impurities

The FDA’s recent announcement, on July 25th, 2023, of the “M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk Guidance for Industry” is a significant development in pharmaceutical regulation. Understanding FDA Guidance The FDA’s guidance serves a crucial purpose: to provide a practical framework applicable to the categorization, … Read more

Posouzení rizika pro nečistoty Nitrosaminu

Posouzení rizika pro nečistoty Nitrosaminu

V dnešním farmaceutickém průmyslu se zaměření na identifikaci a hodnocení nitrosaminů v léčivých produktech a aktivních farmaceutických složkách (API) zintenzivnilo kvůli potenciální karcinogenní povaze těchto nečistot. Nitrosaminy vzbuzují velké obavy, protože mohou být genotoxické, mutagenní a možná i karcinogenní. Detekce nitrosaminových nečistot v běžně předepisovaných lécích pro různé způsoby léčby vyvolává poplach ohledně potenciálních zdrojů … Read more

Évaluation des risques liés aux impuretés nitrosamines

Évaluation des risques liés aux impuretés nitrosamines

Dans l’industrie pharmaceutique d’aujourd’hui, l’accent mis sur l’identification et l’évaluation des nitrosamines dans les produits pharmaceutiques et les ingrédients pharmaceutiques actifs (API) s’est intensifié en raison de la nature potentiellement cancérigène de ces impuretés. Les nitrosamines sont très préoccupantes car elles peuvent être génotoxiques, mutagènes et éventuellement cancérigènes. La détection des impuretés de nitrosamine dans … Read more

FDA Guidance for Industry on the AI Limits for Nitrosamine Drug Substance-Related Impurities

FDA Guidance for Industry on the AI Limits for Nitrosamine Drug Substance Related Impurities

In Pharmaceutical Industry today’s main concern is the identification and presence of nitrosamines in drug products and drug substances. The manufacturers of active pharmaceutical ingredients (APIs) and drug products have the findings of nitrosamine impurities which may be likely human carcinogens and require the need for risk assessment strategy for potential nitrosamines and their presence. … Read more

Pharmacopeial Standards: Ensuring Quality and Safety in Healthcare

Pharmacopeial Standards Ensuring Quality and Safety in Healthcare

In today’s dynamic healthcare landscape, powered by international trade and globalization, the critical role of maintaining and advancing quality standards for medicines cannot be overlooked. These standards are called Pharmacopeial Standards, and they form the bedrock of effective medical treatments, disease prevention, and the protection of public health. As medicines comprise diverse ingredients sourced from … Read more

Avaliação de risco para impurezas de nitrosamina

Avaliacao-de-risco-para-impurezas-de-nitrosamina

Na indústria farmacêutica de hoje, o foco na identificação e avaliação de nitrosaminas em medicamentos e ingredientes farmacêuticos ativos (APIs) se intensificou devido à natureza potencialmente carcinogênica dessas impurezas. As nitrosaminas são motivo de grande preocupação, pois podem ser genotóxicas, mutagênicas e possivelmente cancerígenas. A detecção de impurezas de nitrosamina em medicamentos comumente prescritos usados … Read more

Controle de impurezas de nitrosamina em medicamentos humanos

Controle de impurezas de nitrosamina em medicamentos humanos

Na indústria farmacêutica, os fabricantes de APIs e produtos farmacêuticos têm achados de impurezas de nitrosamina que podem ser prováveis ​​porque os carcinógenos humanos nas drogas eram uma grande preocupação. As agências reguladoras estudaram os detalhes sobre a presença de nitrosamina em alguns dos IFAs e medicamentos. Alguns dos medicamentos, incluindo bloqueadores dos receptores da … Read more

Evaluación De Riesgos De Impurezas De Nitrosamina

Evaluación de riesgos de impurezas de nitrosamina

En la industria farmacéutica actual, el enfoque en la identificación y evaluación de nitrosaminas en productos farmacéuticos e ingredientes farmacéuticos activos (API) se ha intensificado debido a la naturaleza cancerígena potencial de estas impurezas. Las nitrosaminas son motivo de gran preocupación, ya que pueden ser genotóxicas, mutagénicas y posiblemente cancerígenas. La detección de impurezas de … Read more

Control of Nitrosamine Impurities in Human Drugs

Control of Nitrosamine Impurities in Human Drugs

The pharmaceutical industry is committed to producing safe and effective medicines. One aspect that has come under scrutiny is the presence of nitrosamine impurities in APIs and drug products. These impurities, considered potential human carcinogens, have led regulatory agencies to take a closer look. Let’s delve into the imperative task of Control of Nitrosamine Impurities … Read more

[rfq_list]

Request a quote

"*" indicates required fields

Hidden
Products quotation
Name
Url
 
Hidden